ERBB2 and triple-negative breast carcinoma: This clinically heterogeneous disease includes several distinct molecular subtypes, with the four most common being hormone receptor-positive (HR-positive) luminal A and luminal B, human epidermal growth factor receptor 2-positive (HER2-positive), and triple-negative breast cancer (TNBC).